Reduced expression of Bax in small cell lung cancer cells is not sufficient to induce cisplatin-resistance by Biagosch, J et al.
448 october 25, 2010 Eu  Ro  PE  an JouR  nal of MEd  I  cal RE  sEaRcH
Abstract
Resistance to cisplatin in the course of chemotherapy
contributes to the poor prognosis of small cell lung
cancer  (sclc).  B  cell  lymphoma-2  is  the  founding
member of a large family of proteins that either pro-
mote or inhibit apoptosis. We aimed at investigating if
the pro-apoptotic members Bad, Bax, Bim and Bid are
involved in cisplatin-resistance.
cisplatin-resistance  in  the  sclc  cell  line  H1339
was induced by repetitive exposure to cisplatin. Pro-
tein  expression  was  quantified  by  Western  Blot  and
immuno-fluorescence analysis. Protein expression was
altered using siRna interference.
four “cycles” of 0.5 ﾵg/ml cisplatin led to partial
cisplatin-resistance in H1339 cells. the expression of
Bad, Bim and Bid was comparable in na￯ve and resis-
tant cells while the expression of Bax was reduced in
the  resistant  clone.  But,  reducing  Bax  expression  in
na￯ve cells did not lead to altered cisplatin sensitivity
neither in H1339 nor in H187 sclc cells.
We conclude that the reduced Bax expression after
exposure to cisplatin is not sufficient to induce cis-
platin-resistance in sclc cells.
IntRoductIon
In  the  industrial  nations,  lung  cancer  is  the  leading
cause  of  cancer  death  [1].  small  cell  lung  cancer
(sclc) is the most aggressive histological pattern of
lung  cancer.  Platin-based  therapy  regimens  have  be-
come  the  backbone  of  small  cell  lung  cancer
chemotherapy with cisplatin being widely used. first-
line  chemotherapy  with  cisplatin  often  leads  to  en-
couraging responses, but, in the course of the treat-
ment,  resistance  to  cisplatin  is  frequently  observed.
Possible  mechanisms  of  resistance  to  cisplatin  have
been extensively studied and more than 100 proteins
have been suggested to be involved [2, 3]. However, a
satisfying clarification of the underlying mechanisms
is still lacking and none of the proposed proteins has
ever been proven to be clinically relevant. therefore,
the  problem  of  the  development  of  cisplatin-resis-
tance in lung cancer still remains unresolved.
B cell lymphoma-2 (Bcl-2) is the founding member
of a large family of proteins that either promote or in-
hibit apoptosis [4, 5]. the family is typically divided
into  three  groups  according  to  structural  homology
and function. the first group includes anti-apoptotic
proteins with Bcl-2 being the one that has been stud-
ied to the greatest extent. the second group is consti-
tuted by pro-apoptotic proteins including Bcl-2-associ-
ated  x  protein  (Bax).  the  third  group  is  also  pro-
apoptotic and encompasses Bcl-2 homology 3 (BH3)-
only proteins, including Bcl-2-interacting mediator of
cell death (Bim), Bcl-2 antagonist of cell death (Bad),
and BH3 interacting domain death agonist (Bid).
In our study we aimed at investigating if altered ex-
pression of pro-apoptotic members of Bcl-2 family of
proteins  is  involved  in  cisplatin-resistance  in  sclc
cells.
MEtHods
MatERIals
cell culture reagents were obtained from life tech-
nologies (Eggenstein, germany). other reagents were
bought from sigma-aldrich (deisenhofen, germany)
unless  stated  otherwise.  the  human  sclc  cell  line
H1339  was  purchased  from  dsMZ,  Braunschweig,
germany. the human sclc cell line H187 was kindly
provided by Prof. gudermann, department of Physi-
ology, ludwig Maximilians university, Munich.
suRvIval cuRvEs
tumor cells were seeded in 25 cm2 cell culture flask
and cultured for 24 h. next, cells were 3 h exposed to
1 ﾵM cisplatin analogue to the plasma concentration
of unbound cisplatin in humans (6). cell viability was
evaluated by trypan blue exclusion cell counting 24 h
to 96 h after the exposure and expressed as percentage
of untreated control cells.
WEstERn Blot analysIs
H1339  cells  were  washed  twice  with  ice-cold  phos-
phate-buffered  saline  (PBs;  10  mM,  pH  7.4)  and
scraped  in  0,02%  Edta  solution.  the  cell  suspen-
sions  were  treated  according  to  the  manufacturer’s
protocol  using  the  cytobuster  Protein  Extraction
Reagent for soluble proteins (Merck Biosciences, ger-
many). the extracts were collected, aliquoted and then
stored at -20ﾰc until use with Western Blot analysis.
the protein concentrations of the extracts were deter-
mined with the non-Interfering Protein assay Kit ac-
cording  to  the  manufacturer’s  protocol  (Merck  Bio-
sciences,  germany).  the  extracts  were  treated  with
laemmli  sample  buffer  (at  a  final  concentration  of
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12,5% glycerol) at 85ﾰc for 10 min and separated by
sds-PagE on a 10% Bis-tris gel (Invitrogen, cana-
da). staining was performed using specific antibodies
(Bcl-2  family  Rabbit  Monoclonal  antibody  sample
Kit, Epitomics Inc., usa: Bcl-2 dilution 1:1000, Bcl-x
dilution  1:1000,  Bad  dilution  1:2000,  Bag-1  dilution
1:1000, Bak dilution 1:2000, Bax dilution 1:2000, Bim
dilution  1:1000,  Bid  dilution  1:1000,  Mcl-1  dilution
1:1000) and secondary antibody (goat anti-rabbit Igg
(HRP),  santa  cruz  Biotechnology,  usa,  dilution
1:5000).
￟-actin staining served as loading control (mouse
anti-￟-actin HRP, abcam, dilution 1:5000). antibody
complexes  were  visualized  using  Hyperfilm  Ecl
chemiluminescence (amersham Biosciences, uK) and
evaluated using the “Image-J” analysis software.
IMMuno-fluoREsEncE
H1339 cells were grown on microscope slides, fixed
for 5 min in 100% acetone and washed in sHBss con-
taining 10% newborn calf serum (ncs). antibodies
were diluted 1:100 in sHBss with 10% ncs. the cells
were  incubated  for  1  h  at  room  temperature  with
monoclonal  antibodies  (Bcl-2  family  Rabbit  Mono-
clonal  antibody  sample  Kit,  Epitomics  Inc.,  usa).
the cells were than washed in sHBss with 10% ncs
and incubated for 1 h at room temperature with texas
Red conjugated secondary anti-rabbit antibody (santa
cruz Biotechnology, usa). the slides were inspected
on a fluorescence microscope and the fluorescence in-
tensity was quantified using the image analysis soft-
ware “scion”.
sMall IntERfERIng (sI) Rna tRansfEctIon
cells were transfected according to the manufacturer’s
protocol (santa cruz, Biotechnology, usa). the siR-
na concentrations were adapted to ensure the desired
decrease in protein expression without interfering with
cell  viability  and  growth  as  assessed  by  trypan  blue
staining and cell number. H1339 cells were transfected
with 10 ﾵM Bax siRna using the siRna transfection
reagent for 48 h. non-targeting siRna served as con-
trol. after 48 h, protein expression was quantified us-
ing Western Blot analysis. four days after transfection,
protein expression was again quantified to ensure sta-
ble transfection for the duration of the experiments
with cisplatin.
statIstIcs
one-way or two-way anova or “anova repeated
measurements”  (combined  with  pairwise  multiple
comparisons) were performed using the “sigma stat”
software (Jandel scientific, chicago, Il). a P value of
less than 0.05 was considered statistically significant.
REsults
analogue  to  the  plasma  concentration  of  unbound
cisplatin in humans [6], H1339 cells were exposed to
0.5 ﾵg/ml cisplatin for 3 h. the cells that had survived
were allowed to recover for 7 days and were again ex-
posed to 0.5 ﾵg/ml cisplatin. after 4 “cycles”, the sur-
vival after a 5th exposure was compared to the sur-
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Fig.  1.  H1339 human small cell lung cancer cells were ex-
posed to 0.5 ﾵg/ml cisplatin for 3 h. the cells that had sur-
vived were allowed to recover for 7 days and were again ex-
posed to 0.5 ﾵg/ml cisplatin. after 4 “cycles”, the survival af-
ter  a  5th  exposure  was  compared  to  the  survival  of  na￯ve
cells. Pre-treated cells showed an increased survival fraction
compared to na￯ve cell (* = P < 0.01).
Fig.  2.  the expression of
members of the Bcl-2 fam-
ily of proteins was studied
in  na￯ve  and  resistant
H1339 cells using Western
Blot. (a) the expression of
Bax was lower in resistant
cells  (n  =  3,  P  <  0.05)
while  the  expression  of
Bad, Bim and Bid showed
no  difference.  (B)  Repre-
sentative Western Blots.
4) Bergner##_Umbruchvorlage  15.10.10  18:59  Seite 449vival of na￯ve cells. the pretreated cells showed an in-
creased survival fraction compared to na￯ve cells indi-
cating partial resistance to cisplatin (fig. 1). the cis-
platin sensitivity was assessed for up to 5 passages but
no change in cisplatin-resistance could be observed.
next, the expression of the pro-apoptotic members
of the Bcl-2 family of proteins Bad, Bax, Bim and Bid
in na￯ve and resistant H1339 cells was assessed using
Western Blot analysis. from the proteins tested, only
Bax showed an altered expression with the expression
being lower in the cisplatin-resistant clone (fig. 2). to
confirm the result of a reduced Bax expression ob-
tained with Western Blot, we performed immuno-flu-
orescence analysis. again, the fluorescence levels were
lower in the resistant cells (fig. 3).
We next aimed to investigate if the decreased ex-
pression of Bax in the resistant clone was causative for
the cisplatin-resistance or an epiphenomenon. using
siRna  the  expression  of  Bax  was  lowered  in  na￯ve
cells (fig. 4a). But, no difference in cisplatin-sensitivi-
ty of na￯ve cells with reduced or unaltered Bax expres-
sion  could  be  observed  (fig.  4B).  using  a  different
sclc cell line, H187, the experiments of the effect of
reduced  Bax  expression  on  cisplatin  sensitivity  were
repeated. again, no difference in cisplatin sensitivity
could be observed (fig. 5).
dIscussIon
In this study, we have shown that repeated exposure to
cisplatin  led  to  cisplatin-resistance  in  H1339  sclc
cells. from the pro-apoptotic Bcl-2 family of pro-
teins members Bad, Bax, Bim and Bid only the expres-
sion of Bax was reduced in cisplatin-resistant H1339
cells. But, reducing Bax expression in na￯ve sclc cells
did not lead to altered cisplatin-sensitivity.
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Fig. 3. the expression of Bax was assessed in na￯ve and re-
sistant H1339 cells using immuno-fluorescence and found to
be lower in resistant cells (n = 20 , P < 0.01). 
Fig. 4. a na￯ve H1339 cells were 48 h treated with 10 ﾵM
siRna targeting Bax. as a result, the expression of Bax was
reduced compared to na￯ve cells treated with non-targeting
Rna. B na￯ve H1339 cells with a reduced expression of Bax
(na￯ve  siRna)  and  sham  treated  na￯ve  H1339  cells  (na￯ve
ntRna) were exposed to 0.5 ﾵg/ml cisplatin for 3 h. no dif-
ference in the cisplatin-sensitivity could be observed.
Fig. 5. a na￯ve H187 sclc cells were 48 h treated with 10
ﾵM siRna targeting Bax. as a result, the expression of Bax
was reduced compared to na￯ve cells treated with non-target-
ing Rna. B na￯ve H187 cells with a reduced expression of
Bax (na￯ve siRna) and sham treated na￯ve H187 cells (na￯ve
ntRna) were exposed to 0.5 ﾵg/ml cisplatin for 3 h. no dif-
ference in the cisplatin-sensitivity could be observed.
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apoptotic stimuli lead to translocation of Bax and
Bad  to  the  mitochondria,  which  results  in  increased
permeability of the mitochondrial double membrane
[7].  this  in  turn  causes  release  of  cytochrome  c,
which initiates the caspase cascade finally leading to
apoptotic cell death. Bim and Bid have been shown to
bind to Bax thereby activating this pro-apoptotic pro-
tein [7].
cisplatin resistant cells somehow escape the apop-
totic  stimulus  caused  by  the  cross  linking  of  dna
base  pairs  through  cisplatin.  Multiple  mechanisms
have been proposed to cause cisplatin resistance [2, 3]
including  the  intracellular  ca2+-homeostasis  by  our
group [8]. given their pro-apoptotic effects a reduced
expression of Bad, Bax, Bim and Bid in cancer cells
could cause cisplatin resistance. Indeed, we found the
expression of Bax to be reduced using Western Blot
analysis and immuno-fluorescence.
to  test  if  the  reduced  expression  in  deed  con-
tributes to cisplatin resistance we could have increased
the expression in resistant cells or decreased the ex-
pression in na￯ve cells. as siRna constitutes a conve-
nient and readily available tool we decided to do the
latter. But, reduction in Bax expression did not alter
cisplatin sensitivity. the interpretation of this finding
could  be  that  reduction  in  Bax  expression  is  an
epiphenomenon and not related to cisplatin resistance.
alternatively, Bax expression is one of several factors
contributing to but not being sufficient for altered cis-
platin sensitivity.
sakakura et al. overexpressed Bax in Mcf-7 breast
cancer cells and increased thereby cisplatin sensitivity
[9]. also in breast cancer cell lines, gibson et al. re-
ported increased Bax expression following chemother-
apy with cyclophosphamide [10]. these findings con-
flict with our data, but, however, different cell lines
and chemotherapy were used.
taken together we conclude that the reduced Bax
expression after exposure to cisplatin is not sufficient
to induce cisplatin resistance in sclc cells.
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